Your browser doesn't support javascript.
loading
Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study.
Pellegrini, Ilaria; Drabbe, Cas; Grünhagen, Dirk J; Van de Sande, Michiel A J; de Haan, Jacco J; Keymeulen, Kristien B M I; Bonenkamp, Johannes J; Van der Graaf, Winette T A; Husson, Olga.
Afiliación
  • Pellegrini I; Department of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Drabbe C; Department of Medical Oncology, IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Grünhagen DJ; Department of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Van de Sande MAJ; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
  • de Haan JJ; Department of Surgical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
  • Keymeulen KBMI; Department of Orthopaedic Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Bonenkamp JJ; Department of Medical Oncology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
  • Van der Graaf WTA; Department of Surgical Oncology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
  • Husson O; Department of Surgical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Cancers (Basel) ; 14(24)2022 Dec 11.
Article en En | MEDLINE | ID: mdl-36551585
ABSTRACT
Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care.

METHODS:

A cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care.

RESULTS:

In total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22-2.25; p = 0.001); having ≥1 comorbidities and receiving any treatment other than surgery alone with 1.5 (95% CI 1.07-2.05; p = 0.017) and 1.4 (95% CI 1.06-1.98; p = 0.020) higher odds, respectively. Patients on active follow-up had 1.7 higher odds (95% CI 1.20-2.61; p = 0.004) and patients with higher levels of FCR scored lower on the global health status scale (72 vs. 83 p ≤ 0.001).

CONCLUSIONS:

Severe FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos
...